SCHEMBL20206024

SCHEMBL20206024

O=S(=O)(Cc1ccccc1)C1CCN(S)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.45
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
KCNH2 Q12809 2/20 0.43
HTR2C P28335 1/20 0.43
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.40
FAAH O00519 1/20 0.40
PRSS1 P07477 1/20 0.40
PRSS2 P07478 1/20 0.40
ELANE P08246 1/20 0.40
PRTN3 P24158 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18460809 0.83 HTR2A (0.47) HTR2AHPGDTSHRKCNH2HTR2C
SCHEMBL8551473 0.82 HTR2A (0.68) HTR2ATSHRKCNH2HTR2CNPC1
Hydrochloric Acid SCHEMBL8552504 0.81 HTR2A (0.66) HTR2ANPC1POLBALDH1A1SMN1; SMN2
SCHEMBL20069159 0.81 HTR2A (0.50) HTR2AHPGDKCNH2HTR2CNPC1
SCHEMBL21234184 0.80 HPGD (0.51) HPGDTSHRCA1CA2MMP1
SCHEMBL20069160 0.80 HRH3 (0.46) HTR2AHPGDTSHRKCNH2HTR2C
SCHEMBL3244251 0.79 HPGD (0.54) HPGDTSHRCA1CA2MMP1
SCHEMBL10799310 0.76 NPSR1 (0.43) HTR2AHPGDTSHRKCNH2HTR2C
SCHEMBL20148042 0.76 KDM4E (0.47) HTR2ATSHRNPSR1KMT2A
SCHEMBL24969444 0.76 CRBN (0.43) HTR2AHPGDTSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HTR2A 4515/4885HPGD 3857/4885TSHR 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.